In brief: Acrux, Proteome Systems, Panbio, Virax

By Staff Writers
Tuesday, 31 January, 2006

Ross Dobinson has been appointed as Acrux's (ASX:ACR) non-executive chairman, replacing Nuno D'Aquino who is stepping down due to private commitments. D'Aquino will continue as a non-executive director and will chair the board's Human Capital Committee.

Dobinson is a founder and former CEO of Acrux and has an 8 per cent interest in the company's shares. Ken Windle, an Acrux director since 2001, has been appointed non-executive deputy chairman.

Following a letter of intent announced at BIO 2005, Proteome Systems (ASX:PXL) has signed a formal agreement with the Bill Gates-funded Foundation for Innovative New Diagnostics (FIND) to develop Proteome's tuberculosis biomarkers for incorporation into a point-of-care test. The agreement details development milestones and financial and non-financial commitments.

Panbio (ASX:PBO) has appointed Peter Burrows as CFO and company secretary permanently. He was originally appointed on an interim basis on August 27.

Virax Holdings (ASX:VHL) has raised a further $600,000 under its rights issue, bringing the total raised to $3.7 million out of $3.8 million. The issue will close on February 15.